Literature DB >> 28543396

Functional and Structural Assessment of the Effect of Human Umbilical Cord Blood Mesenchymal Stem Cells in Doxorubicin-Induced Cardiotoxicity.

Somia H Abd Allah1, Samia Hussein1, Mai M Hasan2, Raghda H A Deraz3, Wafaa F Hussein3, Laila M E Sabik3.   

Abstract

Cardiomyopathy induced by doxorubicin (DOX) was recognized at an early stage and also several years after drug administration. Mesenchymal stem cells (MSCs) have many properties that make them suitable for preventive and/or regenerative therapies. In this study, we evaluated the effect of MSCs in the functional and the structural improvement of DOX-induced cardiomyopathy in rats. Ninety adult male albino rats were randomly divided into three equal groups of thirty rats each: Group I (control): rats received normal saline. Group II (DOX- group): rats received DOX. Group III (DOX-MSCs group): rats received DOX for 2 weeks then human umbilical cord blood mesenchymal stem cells (hUCB-MSCs). Rats in all groups were evaluated for: physical condition, electrocardiography (ECG), and hemodynamic parameters. Serum cardiac troponin I (cTnI), malondialdehyde (MDA), total antioxidant capacity (TAC), and DNA fragmentation on heart tissue isolated DNA were estimated for evaluation of the mechanism and the extent of the damage. Hearts were examined histopathologically for detection of MSCs homing, structural evaluation, with counting of the collagen fibers for evaluation of fibrosis. DOX-administered rats showed significant functional and structural deterioration. DOX-MSCs treated rats (group III) showed improved functional and structural criteria with restoration of all biochemical indicators of cardiac damage and reactive oxygen species (ROS) to normal, as well. In Conclusion, hUCB-MSCs significantly ameliorated the cardiotoxic manifestations as shown by biochemical, functional, and structural cardiac improvement. J. Cell. Biochem. 118: 3119-3129, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  DOXORUBICIN-INDUCED CARDIOTOXICITY; MESENCHYMAL STEM CELLS; RATS

Mesh:

Substances:

Year:  2017        PMID: 28543396     DOI: 10.1002/jcb.26168

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

Review 1.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

Review 2.  The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity.

Authors:  Huanrong Lan; Qi Xue; Yuyao Liu; Ketao Jin; Xingliang Fang; Hong Shao
Journal:  Cell Tissue Res       Date:  2021-01-12       Impact factor: 5.249

3.  A Study of the Effects of Doxorubicin-Containing Liposomes on Osteogenesis of 3D Stem Cell Spheroids Derived from Gingiva.

Authors:  Hyunjin Lee; Jihwan Son; Sae Kyung Min; Chae-Bin Na; Gawon Yi; Heebeom Koo; Jun-Beom Park
Journal:  Materials (Basel)       Date:  2019-08-23       Impact factor: 3.623

Review 4.  Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review.

Authors:  Cecilie Hoeeg; Sabina Frljak; Abbas Ali Qayyum; Bojan Vrtovec; Jens Kastrup; Annette Ekblond; Bjarke Follin
Journal:  Biomedicines       Date:  2020-12-05

5.  Infusion of two-dose mesenchymal stem cells is more effective than a single dose in a dilated cardiomyopathy rat model by upregulating indoleamine 2,3-dioxygenase expression.

Authors:  Chenyi Gong; Lei Chang; Xuan Sun; Yu Qi; Rong Huang; Ke Chen; Bin Wang; Lina Kang; Lian Wang; Biao Xu
Journal:  Stem Cell Res Ther       Date:  2022-08-12       Impact factor: 8.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.